NCT03879694 2026-02-06
Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors
Roswell Park Cancer Institute
Phase 1 Completed
Clinical Trials
15 trialsNCT05898763 2024-11-07
TEIPP
Erasmus Medical Center
Phase 1/2 Completed
NCT04013672 2024-08-28
Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence
Case Comprehensive Cancer Center
Phase 2 Completed
NCT03617328 2024-02-06
Mel-65
University of Virginia
Phase 1/2 Completed
NCT01176461 2023-01-18
Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT01673217 2022-08-01
Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
Roswell Park Cancer Institute
Phase 1 Completed
NCT03939234 2022-02-21
Peptide Vaccination With PD-L1 and PD-L2 Peptides in Untreated Chronic Lymphatic Leukemia.
Herlev Hospital
Phase 2 Completed
NCT01748747 2018-10-09
Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery
Mayo Clinic
Phase EARLY_PHASE1 Completed
NCT01585350 2016-08-12
MEL58
University of Virginia
Phase 1 Completed
NCT00003224 2014-11-20
Vaccine Therapy in Treating Patients With Metastatic Melanoma
University of Virginia
Phase 1 Completed
NCT00089219 2014-11-20
Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma
University of Virginia
Phase 1/2 Completed
NCT00085189 2014-05-22
Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma
University of Southern California
Phase 2 Completed
NCT00112216 2013-04-24
Immunotherapy of Melanoma Patients
Centre Hospitalier Universitaire Vaudois
Phase 1 Completed
NCT00845611 2012-04-06
Human Leukocyte Antigen (HLA) - A*2402 Restricted Peptide Vaccine Therapy in Patients With Advanced Gastric Cancer
Kinki University
Phase 1 Completed
NCT00912574 2009-06-03
MEL38
University of Virginia
Phase NA Completed